BRIEF published on 08/27/2024 at 13:05, 1 year 5 months ago Pharnext begins liquidation proceedings Creditors Liquidation Paris Commercial Court Pharnext Suspension Of Listing
BRIEF published on 08/27/2024 at 13:05, 1 year 5 months ago Pharnext entame une procédure de liquidation judiciaire Liquidation Judiciaire Tribunal De Commerce De Paris Suspension De Cotation Pharnext Créditeurs
PRESS RELEASE published on 08/27/2024 at 13:00, 1 year 5 months ago Ouverture d'une procédure de liquidation judiciaire Pharnext SCA, société biopharmaceutique en liquidation judiciaire après procédure de conciliation. Suspension de la cotation des actions Biopharmaceutique Liquidation Judiciaire Suspension Cotation Pharnext Procédure Conciliation
BRIEF published on 07/04/2024 at 20:05, 1 year 7 months ago Pharnext announces the termination of the financing contract granted by Néovacs Investors Termination Funding Pharnext Néovacs
BRIEF published on 07/04/2024 at 20:05, 1 year 7 months ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Financement Investisseurs Pharnext Résiliation Néovacs
PRESS RELEASE published on 07/04/2024 at 20:00, 1 year 7 months ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Pharnext annonce la résiliation anticipée du contrat de financement avec Néovacs suite à des cas de défaut. La société sollicite Global Tech Opportunities 13 pour son soutien Financement Pharnext Résiliation Néovacs Global Tech Opportunities
BRIEF published on 06/18/2024 at 18:35, 1 year 8 months ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext Procédure De Conciliation CMT1A PXT3003 Tasly
BRIEF published on 06/18/2024 at 18:35, 1 year 8 months ago Pharnext announces the extension of the conciliation procedure until July 15, 2024 Pharnext Conciliation Procedure CMT1A PXT3003 Tasly
PRESS RELEASE published on 06/18/2024 at 18:30, 1 year 8 months ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 pour poursuivre l'étude clinique de Phase III de PXT3003. Les résultats seront communiqués prochainement Conciliation Étude Clinique Pharnext PXT3003 Maladie Neurodégénérative
BRIEF published on 05/07/2024 at 19:15, 1 year 9 months ago Adjustment of the nominal value at Pharnext Biopharmaceutical Capital Reduction Pharnext Nominal Value Neurodegenerative Diseases
Published on 02/20/2026 at 18:30, 14 minutes ago Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 2 hours 59 minutes ago Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 4 hours 14 minutes ago Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant
Published on 02/20/2026 at 14:08, 4 hours 36 minutes ago Datavault AI Announces Anticipated Launch of Josh Gibson Stablecoin and Josh Gibson NIL Strategies for Its Forthcoming NIL Exchange
Published on 02/20/2026 at 14:00, 4 hours 44 minutes ago Nextech3D.ai's Eventdex Platform Powers AI Matchmaking for the SBA's CT Business Matchmaker Event Featuring Government Agencies and Major Prime Contractors
Published on 02/20/2026 at 18:36, 7 minutes ago EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 12 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:00, 43 minutes ago Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 43 minutes ago Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations
Published on 02/20/2026 at 09:28, 9 hours 15 minutes ago Déclaration du nombre d'actions composant le capital social et du nombre total de droits de vote au 31 janvier 2026
Published on 02/20/2026 at 09:28, 9 hours 15 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of January 31, 2026
